Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .

Essential

These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.
Statistics

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

First successful trial for early detection of HPV-related cancer of the pharynx

No. 54 | 28/09/2022 | by Koh

Screening trials for the early detection of rare diseases often fail due to insufficient predictive power of the results. For the rare HPV-related cancer of the pharynx, scientists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) now relied on the combined detection of antibodies against two different viral proteins in a proof-of concept trial. This enabled them to significantly improve the positive predictive value of the test results.

© DKFZ, Professor Dr. Hanswalter Zentgraf

Oropharyngeal carcinoma, malignant tumors in the mouth and pharynx, are rare and are diagnosed in only 5 to 10 out of 100,000 inhabitants in Germany each year. Men are affected significantly more often than women. Alcohol and tobacco consumption as well as infection with carcinogenic human papillomaviruses (HPV) have been identified as risk factors for this cancer. In Germany, about half of all oropharyngeal cancers are due to HPV, mainly HPV16 is involved. However, the cancer has become more common in the Western world in recent years due to a rapid increase in the rate of HPV-related tumors.

Oropahrynx carcinomas do not form known precursor lesions and are therefore usually detected late, when they have already spread to adjacent lymph nodes. Scientists are therefore looking for biomarkers to identify high-risk patients for whom regular early screening by an otolaryngologist could help detect the dangerous disease as early as possible.

"Serum antibodies against the HPV16 protein E6 are detectable in more than 90 percent of all patients with HPV-related oropharyngeal cancer," says Tim Waterboer of the German Cancer Research Center. But the virologist and epidemiologist points to a fundamental problem with screening for rare diseases: "Because HPV-related oropharyngeal carcinomas are so rare in the general population, the positive predictive power of HPV16 E6 detection is comparatively low. That means, the vast majority people who have antibodies to HPV16 E6, will not develop HPV-related cancer."

Waterboer an colleagues had made the observation that people with HPV-related oropharyngeal cancer not only form antibodies to HPV16 E6, but also to other HPV16 proteins formed during the early phase of viral infection (esp. E1, E2, E7). This situation is almost never found in individuals who do not have HPV-related tumors.

"Our hypothesis was that combined detection of antibodies to HPV16 E6 and at least one other early HPV16 protein could significantly improve the predictive power of a screening examination," Waterboer said.

Waterboer and colleagues were able to verify this assumption in participants of the Hamburg City Health Study, one of the largest health trials in Germany. Blood samples from 4424 participants recruited into the study between 2016 and 2017 were tested for the antibody combination. The researchers found antibodies to HPV16 E6 in 35 people (0.8 percent). But only eleven of the participants (0.3 percent) were seropositive for HPV16 E6 plus another early HPV16 protein.

These eleven high-risk individuals were subsequently invited to regular examinations at six-month intervals at the Department of Otolaryngology at the University Medical Center Hamburg-Eppendorf. Nine of the participants attended these examinations. During the following 1.3 years, HPV-related oropharyngeal carcinomas were diagnosed in three asymptomatic participants. The cancers were detected at stage 1 and were successfully treated.

"Early detection of these carcinomas significantly improves the quality of life of those affected. Typical consequences after the treatment of large tumors are, for example, swallowing and speech disorders, which massively reduce the quality of life of the patients. At an early stage, oropharyngeal carcinomas can be treated comparatively gently, so that patients have hardly any therapy-related restrictions," says Waterboer.

He emphasizes that the current work is a proof-of-concept study. "In many cases, there was an expectation that screening for oropharyngeal cancer would inevitably lead to an unacceptably high rate of false positive results due to the rarity of the disease. We were able to address that fear with the combined antibody analysis."

Next, Waterboer and colleagues plan to include additional biomarkers and clinical examinations, as well as imaging techniques, to define the optimal conditions for screening for HPV-related oropharyngeal cancer. Only then will it be possible to assess whether a population-wide use of such a screening examination could be useful under medical and also economic aspects.

Eike Burandt, Krystle Lang Kuhs, Michael Pawlita, Tim Waterboer, Nicole Brenner: Detection of stage I HPV-driven oropharyngeal cancer in asymptomatic individuals in the Hamburg City Health Study using HPV16 E6 serology – a proof-of-concept study.
eClinical Medicine 2022, DOI: https://doi.org/10.1016/j.eclinm.2022.101659 

The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) with its more than 3,000 employees is the largest biomedical research institution in Germany. More than 1,300 scientists at the DKFZ investigate how cancer develops, identify cancer risk factors and search for new strategies to prevent people from developing cancer. They are developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to all questions on cancer.

Jointly with partners from the university hospitals, the DKFZ operates the National Center for Tumor Diseases (NCT) in Heidelberg and Dresden, and the Hopp Children's Cancer Center KiTZ in Heidelberg. In the German Consortium for Translational Cancer Research (DKTK), one of the six German Centers for Health Research, the DKFZ maintains translational centers at seven university partner locations. NCT and DKTK sites combine excellent university medicine with the high-profile research of the DKFZ. They contribute to the endeavor of transferring promising approaches from cancer research to the clinic and thus improving the chances of cancer patients.

The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.

RSS-Feed

Subscribe to our RSS-Feed.

to top
powered by webEdition CMS